Dr. Ahmad Doroudian reports

BETTERLIFE ENGAGES SYNER-G TO OVERSEE GMP MANUFACTURING OF BETR-001 FOR IND AND PHASE 1

Betterlife Pharma Inc. has entered into an agreement with Syner-G BioPharma Group to oversee good manufacturing practice manufacturing of BETR-001 for its planned investigational new drug and phase 1 program.

BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is active against neuroreceptors involved in migraines and cluster headaches, as well as neuroreceptors involved in psychiatric disorders such as depression and anxiety. While it is a potent neuroplastogen and an agonist of the 5-HT2A, 5-HT1B, 5-HT1D and 5-HT1F receptors, BETR-001 is designed to be non-hallucinogenic and is not a 5-HT2B agonist. Betterlife believes BETR-001 will mimic the projected therapeutic potential of LSD without causing its undesirable side effects, such as hallucinations and potential cardiac side effects due to LSD agonism of 5-HT2B receptors. BETR-001 is completing its final IND-enabling studies and projected to file its IND and start phase 1 trials in first quarter 2027.

BETR-001 is being developed initially for chronic cluster headache and chronic migraine, two disabling headache disorders with substantial unmet medical need. Chronic cluster headache causes severe, recurrent attacks that respond poorly to existing therapies, and many chronic migraine patients exhaust available preventives without durable relief. BETR-001 engages the 5-HT1B, 5-HT1D and 5-HT1F receptors, the serotonergic targets of approved migraine therapies, and its neuroplastogenic activity may support a more durable treatment effect. The company plans to advance BETR-001 into phase 1A-1B as the first step toward clinical proof of concept in these patients.

"We are pleased to be partnering with Syner-G to oversee the proprietary manufacturing of BETR-001. Their CMC and regulatory expertise strengthen our path to an IND filing and the start of phase 1 in the first quarter of 2027," said Dr. Ahmad Doroudian, Betterlife's chief executive officer.

"We are pleased to partner with Betterlife to advance BETR-001 toward the clinic through GMP manufacturing oversight and integrated development support," said Ron Kraus, chief executive officer of Syner-G. "Our teams share a commitment to advancing innovative therapies efficiently and responsibly, with the goal of bringing new treatment options to patients. We are proud to support this program as it progresses toward IND submission and first-in-human clinical studies."

Betterlife also announces the engagement of Vancouver-based GTM Studios for a period of two months to produce marketing materials for BETR-001. Pursuant to the engagement, GTM will be compensated at a rate of $4,000 per month.

Further to the company's June 22, 2026, press release, the company would like to clarify that the exercise price of the 3.25 million stock options granted on June 15, 2026, is seven cents, not 6.5 cents.

About Betterlife Pharma Inc.

Betterlife is a biotechnology company developing compounds for the treatment of neurological and neuropsychiatric disorders. Its lead candidate, BETR-001, is a non-hallucinogenic LSD-derivative molecule in preclinical development.

We seek Safe Harbor.